Skip to main content Accessibility help

Challenges associated with curcumin therapy in Alzheimer disease

  • Abdenour Belkacemi (a1), Sihem Doggui (a1) (a2), Lé Dao (a2) and Charles Ramassamy (a1) (a3)


Curcumin, the phytochemical agent in the spice turmeric, which gives Indian curry its yellow colour, is also a traditional Indian medicine. It has been used for millennia as a wound-healing agent and for treating a variety of ailments. The antioxidant, anti-inflammatory, antiproliferative and other properties of curcumin have only recently gained the attention of modern pharmacology. The mechanism of action of curcumin is complex and multifaceted. In part, curcumin acts by activating various cytoprotective proteins that are components of the phase II response. Over the past decade, research with curcumin has increased significantly. In vitro and in vivo studies have demonstrated that curcumin could target pathways involved in the pathophysiology of Alzheimer disease (AD), such as the β-amyloid cascade, tau phosphorylation, neuroinflammation or oxidative stress. These findings suggest that curcumin might be a promising compound for the development of AD therapy. However, its insolubility in water and poor bioavailability have limited clinical trials and its therapeutic applications. To be effective as a drug therapy, curcumin must be combined with other drugs, or new delivery strategies need to be developed.


Corresponding author

*Corresponding author: Charles Ramassamy, INRS-Institut Armand-Frappier, 531, boul. des Prairies, H7V 1B7 Laval, Québec, Canada. E-mail:


Hide All
1Querfurth, H.W. and LaFerla, F.M. (2010) Alzheimer's disease. New England Journal of Medicine 362, 329-344
2Ferri, C.P. et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117
3Smith, M.A. (1998) Alzheimer disease. International Review of Neurobiology 42, 1-54
4Kukull, W.A. et al. (2002) Dementia and Alzheimer disease incidence: a prospective cohort study. Archives of Neurology 59, 1737-1746
5Nunan, J. and Small, D.H. (2000) Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Letters 483, 6-10
6Panegyres, P.K. (2001) The functions of the amyloid precursor protein gene. Reviews in the Neurosciences 12, 1-39
7Haass, C. et al. (1993) beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. Journal of Biological Chemistry 268, 3021-3024
8Black, R.A. et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733
9Seubert, P. et al. (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361, 260-263
10De Strooper, B., Vassar, R. and Golde, T. (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature Reviews. Neurology 6, 99-107
11Evin, G., Sernee, M.F. and Masters, C.L. (2006) Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20, 351-372
12Tschape, J.A. and Hartmann, T. (2006) Therapeutic perspectives in Alzheimer's disease. Recent Patients on CNS Drug Discovery 1, 119-127
13Nourooz-Zadeh, J. et al. (1999) F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. Journal of Neurochemistry 72, 734-740
14Ramassamy, C. et al. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radical Biology and Medicine 27, 544-553
15Ramassamy, C. et al. (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiology of Disease 7, 23-37
16Smith, M.A. et al. (1996) Oxidative damage in Alzheimer's. Nature 382, 120-121
17Pratico, D. et al. (2000) Increased 8,12-iso-iPF(2 alpha)-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Annals of Neurology 48, 809-812
18Nam, D.T. et al. (2010) Potential role of acrolein in neurodegeneration and in Alzheimer's disease. Current Molecular Pharmacology 3, 66-78
19Sarkar, D. and Fisher, P.B. (2006) Molecular mechanisms of aging-associated inflammation. Cancer Letters 236, 13-23
20Shehzad, A., Wahid, F. and Lee, Y.S. (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Archiv der Pharmazie 343, 489-499
21Singh, M. et al. (2008) Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. Journal of Agricultural and Food Chemistry 56, 4855-4873
22Ganguli, M. et al. (2000) Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology 54, 1109-1116
23Kiuchi, F. et al. (1993) Nematocidal activity of turmeric: synergistic action of curcuminoids. Chemical and Pharmaceutical Bulletin 41, 1640-1643
24Goel, A., Kunnumakkara, A.B. and Aggarwal, B.B. (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochemical Pharmacology 75, 787-809
25Soni, K.B. and Kuttan, R. (1992) Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian Journal of Physiology and Pharmacology 36, 273-275
26Strimpakos, A.S. and Sharma, R.A. (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants and Redox Signaling 10, 511-545
27Venkatesan, N., Punithavathi, D. and Arumugam, V. (2000) Curcumin prevents adriamycin nephrotoxicity in rats. British Journal of Pharmacology 129, 231-234
28Joe, B. and Lokesh, B.R. (1994) Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochimica et Biophysica Acta 1224, 255-263
29Sreejayan, N. and Rao, M.N. (1994) Curcuminoids as potent inhibitors of lipid peroxidation. Journal of Pharmacy and Pharmacology 46, 1013-1016.
30Cekmen, M. et al. (2009) Curcumin prevents oxidative renal damage induced by acetaminophen in rats. Food and Chemical Toxicology 47, 1480-1484
31El-Demerdash, F.M., Yousef, M.I. and Radwan, F.M. (2009) Ameliorating effect of curcumin on sodium arsenite-induced oxidative damage and lipid peroxidation in different rat organs. Food and Chemical Toxicology 47, 249-254
32Farhangkhoee, H. et al. (2006) Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutrition and Metabolism 3, 27
33Bhaumik, S. et al. (1999) Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Letters 456, 311-314
34Aggarwal, B.B., Kumar, A. and Bharti, A.C. (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Research 23, 363-398
35Cai, Y.Z. et al. (2006) Structure-radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants. Life Sciences 78, 2872-2888
36Jayaprakasha, G.K. et al. (2006) Phenolic constituents in the fruits of Cinnamomum zeylanicum and their antioxidant activity. Journal of Agricultural and Food Chemistry 54, 1672-1679
37Chen, W.F. et al. (2006) Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radical Biology and Medicine 40, 526-535
38Somparn, P. et al. (2007) Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biological and Pharmaceutical Bulletin 30, 74-78
39Gorman, A.A. et al. (1994) Curcumin-derived transients: a pulsed laser and pulse radiolysis study. Photochemistry and Photobiology 59, 389-398
40Schaich, K., Ficher, C. and King, R. (1994) Phytochemicals for cancer prevention II. American Chemical Society 547, 204-222
41Dairam, A. et al. (2007) Curcuminoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. Journal of Agricultural and Food Chemistry 55, 1039-1044
42Ravindran, J. et al. (2010) Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochemical Pharmacology 79, 1658-1666
43Sandur, S.K. et al. (2007) Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28, 1765-1773
44Singh, U. et al. (2011) Reactions of reactive oxygen species (ROS) with curcumin analogues: structure–activity relationship. Free Radical Research 45, 317-325
45Singh, S. and Aggarwal, B.B. (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. Journal of Biological Chemistry 270, 24995-25000
46Jin, C.Y. et al. (2007) Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacologica Sinica 28, 1645-1651
47Xu, Y.X. et al. (1997) Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathology and Molecular Hematology 11, 49-62
48Cho, J.W., Lee, K.S. and Kim, C.W. (2007) Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. International Journal of Molecular Medicine 19, 469-474
49Hong, J. et al. (2004) Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25, 1671-1679
50Wang, H.M. et al. (2010) PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. Journal of Alzheimer's Disease 20, 1189-1199
51Lim, G.P. et al. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience 21, 8370-8377
52Chainani-Wu, N. (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). Journal of Alternative and Complementary Medicine 9, 161-168
53Begum, A.N. et al. (2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 326, 196-208
54Lambert, M.P. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 95, 6448-6453
55Hartley, D.M. et al. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. Journal of Neuroscience 19, 8876-8884
56Necula, M. et al. (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. Journal of Biological Chemistry 282, 10311-10324
57Kim, H. et al. (2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. Journal of Agricultural and Food Chemistry 53, 8537-8541
58Ono, K. et al. (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Journal of Neuroscience Research 75, 742-750
59Yanagisawa, D. et al. (2011) Curcuminoid binds to amyloid-beta1–42 oligomer and fibril. Journal of Alzheimer's Disease 24, 33-42
60Zhang, C. et al. (2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. Journal of Biological Chemistry 285, 28472-28480
61Garcia-Alloza, M. et al. (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. Journal of Neurochemistry 102, 1095-1104
62Demeule, M. et al. (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vascular Pharmacology 38, 339-348
63Romiti, N. et al. (1998) Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sciences 62, 2349-2358
64Yang, F. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry 280, 5892-5901
65Begum, A.N. et al. (2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 326, 196-208
66Frautschy, S.A. et al. (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiology of Aging 22, 993-1005
67Ansari, M.J. et al. (2005) Stability-indicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis 39, 132-138
68Wang, Y.J. et al. (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis 15, 1867-1876
69Cheng, A.L. et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research 21, 2895-2900
70Wahlang, B., Pawar, Y.B. and Bansal, A.K. (2011) Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. European Journal of Pharmaceutics and Biopharmaceutics 77, 275-282
71Ireson, C. et al. (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Research 61, 1058-1064
72Pan, M.H., Huang, T.M. and Lin, J.K. (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolism and Disposition 27, 486-494
73Vareed, S.K. et al. (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiology, Biomarkers and Prevention 17, 1411-1417
74Perkins, S. et al. (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiology, Biomarkers and Prevention 11, 535-540
75Murugan, P. and Pari, L. (2006) Effect of tetrahydrocurcumin on lipid peroxidation and lipids in streptozotocin-nicotinamide-induced diabetic rats. Basic and Clinical Pharmacology and Toxicology 99, 122-127
76Murugan, P. and Pari, L. (2006) Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sciences 79, 1720-1728
77Jeong, S.O. et al. (2009) Dimethoxycurcumin, a synthetic curcumin analogue, induces heme oxygenase-1 expression through Nrf2 activation in RAW264.7 macrophages. Journal of Clinical Biochemistry and Nutrition 44, 79-84
78Shoba, G. et al. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 64, 353-356
79Manju, S. and Sreenivasan, K. (2011) Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. Journal of Pharmaceutical Sciences 100, 504-511
80Gupta, N.K. and Dixit, V.K. (2011) Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. Journal of Pharmaceutical Sciences 100, 1987-1995
81Setthacheewakul, S. et al. (2010) Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. European Journal of Pharmaceutics and Biopharmaceutics 76, 475-485
82Takahashi, M. et al. (2009) Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. Journal of Agricultural and Food Chemistry 57, 9141-9146
83Ghosh, M. et al. (2011) Curcumin nanodisks: formulation and characterization. Nanomedicine 7, 162-167
84Anand, P. et al. (2007) Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics 4, 807-818
85Shaikh, J. et al. (2009) Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. European Journal of Pharmaceutical Sciences 37, 223-230
86Tonnesen, H.H., Masson, M. and Loftsson, T. (2002) Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. International Journal of Pharmaceutics 244, 127-135
87Yallapu, M.M. et al. (2010) Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. Journal of Colloid and Interface Science 351, 19-29
88Mukerjee, A. and Vishwanatha, J.K. (2009) Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Research 29, 3867-3875
89Mohanty, C. and Sahoo, S.K. (2010) The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31, 6597-6611
90Bisht, S. et al. (2007) Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. Journal of Nanobiotechnology 5, 3
91Cui, J. et al. (2009) Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. International Journal of Pharmaceutics 371, 148-155
92Mukerjee, A. and Vishwanatha, J.K. (2009) Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Research 29, 3867-3875
93Sahu, A. et al. (2008) Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomaterialia 4, 1752-1761
94Anand, P. et al. (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochemical Pharmacology 79, 330-338
95Anand, P. et al. (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochemical Pharmacology 79, 330-338
96Duan, J. et al. (2010) Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. International Journal of Pharmaceutics 400, 211-220
97Sahu, A., Kasoju, N. and Bora, U. (2008) Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules 9, 2905-2912
98Song, Z. et al. (2011) Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. Journal of Colloid and Interface Science 354, 116-123
99Sun, M. et al. (2010) Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. Journal of Nanoparticle Research 12, 3111-3122
100Martel, C.L. et al. (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood–brain barrier transport of circulating Alzheimer's amyloid beta. Journal of Neurochemistry 69, 1995-2004
101Mulik, R.S. et al. (2010) ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Molecular Pharmaceutics 7, 815-825
102Khumsupan, P. et al. (2011) Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochimica et Biophysica Acta 1808, 352-359
103Mulik, R.S. et al. (2010) ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Molecular Pharmaceutics 7, 815-825
104Ray, B. et al. (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc (TM)) in the neuronal cell culture and animal model: implications for Alzheimer's disease. Journal of Alzheimer's Disease 23, 61-77
105Panyam, J. and Labhasetwar, V. (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews 55, 329-347
106Hu, Y.L. and Gao, J.Q. (2010) Potential neurotoxicity of nanoparticles. International Journal of Pharmaceutics 394, 115-121
107Wu, W.H. et al. (2008) TiO2 nanoparticles promote beta-amyloid fibrillation in vitro. Biochemical and Biophysical Research Communications 373, 315-318
108Hu, R. et al. (2010) Neurotoxicological effects and the impairment of spatial recognition memory in mice caused by exposure to TiO2 nanoparticles. Biomaterials 31, 8043-8050
109Baum, L. et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Journal of Clinical Psychopharmacology 28, 110-113
110Ringman, J.M. et al. (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92
111Ravindranath, V. and Chandrasekhara, N. (1980) Absorption and tissue distribution of curcumin in rats. Toxicology 16, 259-265
112Sharma, R.A. et al. (2001) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clinical Cancer Research 7, 1452-1458
113Kakkar, V. et al. (2011) Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Molecular Nutrition and Food Research 55, 495-503
114Sharma, R.A. et al. (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clinical Cancer Research 7, 1894-1900

The following papers describe in detail mechanisms of curcumin that are not discussed in this review:

Kulkarni, A.P. et al. (2011) Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease. Current Alzheimer Research 8, 95-113
Mohorko, N. et al. (2010) Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. Journal of Neuropathology and Experimental Neurology 69, 405-414
Seo, J.S. et al. (2010) Severe motor neuron degeneration in the spinal cord of the Tg2576 mouse model of Alzheimer disease. Journal of Alzheimer's Disease 21, 263-276
Reeta, K.H. et al. (2011) Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats. Pharmacology, Biochemistry and Behavior 99, 399-407

General information on curcumin, on curcumin and cancer and a list of clinical trials:


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed